Tovorafenib

(TOH-voh-RA-feh-nib)

This page contains brief information about tovorafenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Ojemda

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Tovorafenib is approved to treat:

Glioma that is low grade, has come back or did not respond to treatment, and has an abnormal BRAF gene. It is used in children aged 6 months and older.

Tovorafenib is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Tovorafenib is also being studied in the treatment of other types of cancer.

More About Tovorafenib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Tovorafenib Approved for Some Children with Low-Grade Glioma

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Tovorafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.